Skip to main content
Erschienen in: Wiener klinische Wochenschrift 1-2/2014

01.01.2014 | original article

Evaluation of the effect of comorbidity on survival in pancreatic cancer by using “Charlson Comorbidity Index” and “Cumulative Illness Rating Scale”

verfasst von: F. Tugba Kos, Ozan Yazici, Burak Civelek, Metin Seker, Zafer Arik, Sercan Aksoy, Dogan Uncu, Nuriye Ozdemir, Nurullah Zengin

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2014

Einloggen, um Zugang zu erhalten

Summary

Background

Effect of comorbidity on the treatments that patients receive is not clear, as healthy elderly patients and the elderly with less comorbid diseases are included in the studies. In the present study, the effect of comorbidity on the survival was evaluated using Charlson Comorbidity Index (CCI) and Cumulative Illness Rating Scale (CIRS).

Material and method

The general features and comorbid diseases of the pancreatic cancer patients were retrospectively screened from the patient files using the automated system. CCI and CIRS were used as the comorbidity indices.

Results

A total of 106 patients with pancreatic cancer were included in the study. The median overall survival rate was 9.0 [95 % confidence interval (CI): 6.7–11.3] months. The median overall survival rate was found as 9.4 (95 % CI: 6.7–12.1) months in the patients whose CCI score was ≤ 2 and was found as 6.2 (95 % CI: 4.0–8.3) months in the patients with CCI scores ≥ 3 (p = 0.05). The median overall survival rate was calculated as 9.8 (95 % CI: 6.3–13.4) months in the patients with CIRS scores ≤ 2 and was calculated as 8.3 (95 % CI: 6.0–10.6) months in the patients with CIRS scores ≥ 3 (p = 0.51). When surgery, radiotherapy, grading, and CCI score were evaluated using multivariate analysis, it was observed that only the treatment modality had a significant effect on the survival rate.

Conclusion

The results on the use of comorbidity indices are contradictory for the cancers with lower survival rates such as pancreatic cancer. New prognostic scales might be developed for this patient group by considering the side effects of chemotherapy.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRef
3.
Zurück zum Zitat Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 3. 2006;19(3):CD002093. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 3. 2006;19(3):CD002093.
4.
Zurück zum Zitat Burris 3rd HA, Moore, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: randomized trial. J Clin Oncol. 1997;15(6):2403–13.PubMed Burris 3rd HA, Moore, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: randomized trial. J Clin Oncol. 1997;15(6):2403–13.PubMed
5.
Zurück zum Zitat Neuhaus P, Riess H, Post S, et al. CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC J Clin Oncol., 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).2008;26:(15S) (May 20 Supplement). Neuhaus P, Riess H, Post S, et al. CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC J Clin Oncol., 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).2008;26:(15S) (May 20 Supplement).
6.
Zurück zum Zitat Marechal R, Demols A, Gay F, et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas. 2008;36(3):16–21.CrossRef Marechal R, Demols A, Gay F, et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas. 2008;36(3):16–21.CrossRef
7.
Zurück zum Zitat Nakai Y, Isayama H, Sasaki T, et al. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol. 2011;78(3):252–9.PubMedCrossRef Nakai Y, Isayama H, Sasaki T, et al. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol. 2011;78(3):252–9.PubMedCrossRef
8.
Zurück zum Zitat Lichtman SM, Wildiers H, Chatelut E, et al. International society of geriatric oncology chemotherapy taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature. J Clin Oncol. 2007;25(14):1832–43.PubMedCrossRef Lichtman SM, Wildiers H, Chatelut E, et al. International society of geriatric oncology chemotherapy taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature. J Clin Oncol. 2007;25(14):1832–43.PubMedCrossRef
9.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef
10.
Zurück zum Zitat Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582–7.PubMed Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582–7.PubMed
11.
Zurück zum Zitat Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622–6.PubMed Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622–6.PubMed
12.
Zurück zum Zitat Aksoy S, Aksoy H, Harputluoglu H, Kilickap S, Altundag K. Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer. Med Hypotheses. 2006;67(4):744–6.PubMedCrossRef Aksoy S, Aksoy H, Harputluoglu H, Kilickap S, Altundag K. Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer. Med Hypotheses. 2006;67(4):744–6.PubMedCrossRef
13.
Zurück zum Zitat Land LH, Dalton SO, Jensen MB, Ewertz M. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer. 2012;107(11):1901–7.PubMedCentralPubMedCrossRef Land LH, Dalton SO, Jensen MB, Ewertz M. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer. 2012;107(11):1901–7.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer. 2001;92(8):2109–16.PubMedCrossRef Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer. 2001;92(8):2109–16.PubMedCrossRef
15.
Zurück zum Zitat Juan O, Albert A, Campos JM, Caranyana V, Muñoz J, Alberola V. Measurement and impact of co-morbidity in elderly patients with advanced non small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel. Acta Oncol. 2007;46(3):367–73.PubMedCrossRef Juan O, Albert A, Campos JM, Caranyana V, Muñoz J, Alberola V. Measurement and impact of co-morbidity in elderly patients with advanced non small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel. Acta Oncol. 2007;46(3):367–73.PubMedCrossRef
16.
Zurück zum Zitat Lee KJ, Yi SW, Chung MJ, et al. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013;54(3):643–9.PubMedCentralPubMedCrossRef Lee KJ, Yi SW, Chung MJ, et al. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013;54(3):643–9.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25(16):2212–7.PubMedCrossRef Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25(16):2212–7.PubMedCrossRef
18.
Zurück zum Zitat Vickers MM, Powell ED, Asmis TR, et al. Comorbidity, age and overall survival in patients with advanced pancreastic cancer results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotnib or placebo. Eur J Cancer. 2012;48(10):1434–42.PubMedCrossRef Vickers MM, Powell ED, Asmis TR, et al. Comorbidity, age and overall survival in patients with advanced pancreastic cancer results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotnib or placebo. Eur J Cancer. 2012;48(10):1434–42.PubMedCrossRef
19.
Zurück zum Zitat Sarfati D. Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol. 2012;65(9):924–33.PubMedCrossRef Sarfati D. Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol. 2012;65(9):924–33.PubMedCrossRef
Metadaten
Titel
Evaluation of the effect of comorbidity on survival in pancreatic cancer by using “Charlson Comorbidity Index” and “Cumulative Illness Rating Scale”
verfasst von
F. Tugba Kos
Ozan Yazici
Burak Civelek
Metin Seker
Zafer Arik
Sercan Aksoy
Dogan Uncu
Nuriye Ozdemir
Nurullah Zengin
Publikationsdatum
01.01.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0453-9

Weitere Artikel der Ausgabe 1-2/2014

Wiener klinische Wochenschrift 1-2/2014 Zur Ausgabe

gesellschaft der ärzte in wien

Billrothhaus.TV